Statistical Challenges in the Identification, Validation, and Use of Surrogate Markers
Videos from CMO Workshop
Layla Parast, University of Texas at Austin
Monday Aug 22, 2022 09:00 - 09:34
Workshop Background, Overview, Goals, and Structure
Geert Molenberghs, Universiteit Hasselt & KU Leuven
Monday Aug 22, 2022 09:30 - 10:31
The Statistical Evaluation of Surrogate Endpoints in Clinical Trials
Marc Buyse, Hasselt University and IDDI
Monday Aug 22, 2022 11:00 - 11:28
Statistical Evaluation of Surrogate Endpoints
Mark van der Laan, University of California Berkeley
Monday Aug 22, 2022 11:30 - 12:36
The Oracle Surrogate and Sequential Adaptive Designs that Learn Optimal Individualized Treatment Rules by Utilizing Surrogate Outcomes
Larry Han, Harvard University
Monday Aug 22, 2022 14:00 - 14:29
Challenges of surrogate markers in real-world data
Tyler VanderWeele, Harvard Public Health
Monday Aug 22, 2022 14:30 - 14:58
Criteria for the Use of Surrogates
Aline Talhouk, University of British Columbia
Monday Aug 22, 2022 15:00 - 15:30
Surrogate markers in endometrial cancer prevention trials
Peter Gilbert, Fred Hutchinson Cancer Center
Tuesday Aug 23, 2022 09:00 - 09:33
Interventional (Controlled, Natural, Stochastic) and Principal Stratification Causal Effects for Evaluation and Use of Surrogate Endpoints
Erin Gabriel, Karolinska Institutet
Tuesday Aug 23, 2022 09:30 - 09:58
Flexible evaluation of surrogacy in Bayesian adaptive platform studies
Boris Hejblum, Inserm Bordeaux Population Health
Tuesday Aug 23, 2022 10:00 - 10:31
Potential of Early Transcriptomics as First Surrogate for Vaccine Response
Michael Elliott, University of Michigan
Tuesday Aug 23, 2022 11:00 - 11:29
Measures of Surrogate Paradox Risk using Data from Multiple Trials
An Vandebosch, Janssen Pharmaceuticals
Tuesday Aug 23, 2022 11:30 - 12:00
Statistical Challenges and Methods to Identify Surrogate Markers in Vaccine Trials: An Industry Perspective
Ronghui (Lily) Xu, University of California at San Diego
Tuesday Aug 23, 2022 14:00 - 14:32
Causal Effects of Prenatal Drug Exposure on Birth Defects with Missing by Terathanasia
Fei Gao, Fred Hutchinson Cancer Research Center
Tuesday Aug 23, 2022 14:30 - 15:01
Estimating Counterfactual Placebo HIV Incidence in HIV Prevention Trials Without Placebo Arms Based on Markers of HIV Exposure
Emily Roberts, University of Michigan
Wednesday Aug 24, 2022 14:00 - 14:33
Causal inference methods to validate surrogate endpoints with time-to-event data
Sihai Zhao, University of Illinois at Urbana-Champaign
Wednesday Aug 24, 2022 14:30 - 15:01
Surrogate Markers and Mediation Analysis
Xuekui Zhang, University of Victoria
Wednesday Aug 24, 2022 15:30 - 16:01
The impact of lockdown timing on COVID-19 transmission across US counties
Kangyi(Ken) Peng, Simon Fraser University
Wednesday Aug 24, 2022 16:00 - 16:38
Prediction for Covid-19 hospitalizations using Sars-Cov-2 wastewater surveillance data in Ottawa, Canada
Denis Agniel, RAND
Thursday Aug 25, 2022 09:00 - 09:29
Evaluating Longitudinal and High-dimensional Surrogate Markers
Dean Follmann, National Institute of Allergy and Infectious Disease
Thursday Aug 25, 2022 09:30 - 09:59
Experimental Manipulations to Support Surrogate Markers
Grace Yi, University of Western Ontario
Thursday Aug 25, 2022 10:00 - 10:39
Analysis of Noisy Survival Data with Graphical Proportional Hazards Measurement Error Model
Tanya Garcia, UNC Chapel Hill
Thursday Aug 25, 2022 11:00 - 11:29
Robust Estimators to Build Reliable Disease Trajectories from Short Longitudinal Data
Leilei Zeng, University of Waterloo
Thursday Aug 25, 2022 12:00 - 12:33
Design and Analysis Considerations for Using Progression-free Survival in Cancer Trials
